On April 27, 2026, Intellia Therapeutics reported positive Phase 3 results for lonvo-z (lonvoguran ziclumeran), a one-time CRISPR gene-editing therapy for hereditary angioedema (HAE). A single IV infusion cut monthly HAE attacks by 87% versus placebo. 62% of treated patients went the entire 6-month efficacy period both attack-free and therapy-free, compared with 11% of patients on placebo. The trial met its primary endpoint and all key secondary endpoints (Intellia, 2026).
The numbers matter. The bigger story is what they represent. HAELO is the first Phase 3 success ever recorded for an in vivo gene-editing therapy in human medicine. For HAE patients, a one-time infusion may eventually replace years of subcutaneous injections, IV concentrate infusions, or daily oral pills. For the broader rare disease world, it's a proof point that in vivo gene editing can clear pivotal trials.
What HAE Actually Looks Like
Hereditary angioedema is rare. About 1 in 50,000 people worldwide carry it (Cicardi et al., Allergy 2014). For the people who do have it, the disease shapes nearly every decision about travel, work, and family. Patients form rapid swelling in unpredictable parts of the body: the face, lips, abdomen, hands, feet, and most dangerously the airway. Abdominal attacks can be mistaken for surgical emergencies. Laryngeal attacks can close the airway entirely. Before the modern treatment era, mortality from untreated HAE attacks ran 20% to 30% (StatPearls, NIH 2024).
Without prophylaxis, attacks are common. A US HAEA registry of more than 600 patients found that most experienced multiple swelling episodes per month, with attack rates ranging from a few per year to more than once per week (Riedl et al., Annals of Allergy 2023). The unpredictability is the hardest part. Patients describe planning their lives around proximity to a hospital, packing rescue medication for every flight, and avoiding situations where help might not arrive fast enough.
How HAE Got Treated, in 144 Years
Heinrich Quincke documented angioneurotic edema in 1882. William Osler described its hereditary form in 1888. Treatment had to wait. The mechanism wasn't pinned down until 1963, when Donaldson and Evans showed that HAE patients lack functional C1 esterase inhibitor (C1-INH), the protein that keeps the body's bradykinin pathway in check. When C1-INH is absent or non-functional, bradykinin builds up. Bradykinin causes blood vessels to leak. Tissue swells (Donaldson and Evans, American Journal of Medicine, 1963).
Drug development followed slowly. Plasma-derived C1-INH concentrate (Cinryze) won FDA approval in 2008, giving patients a way to replace the missing protein. Berinert added another C1-INH option in 2009. Icatibant (Firazyr) attacked the cascade further downstream in 2011. Recombinant C1-INH (Ruconest) followed in 2014. Each step reduced attacks but kept patients on lifelong therapy.
The biggest single advance before 2026 was Takhzyro (lanadelumab), the first monoclonal antibody for HAE prophylaxis, approved in 2018. The pivotal HELP study showed an 87% reduction in monthly attack rate versus placebo, with 44% of patients attack-free over the 26-week treatment period (Banerji et al., JAMA 2018). Two years later, Orladeyo (berotralstat) became the first oral plasma kallikrein inhibitor approved for prophylaxis, in late 2020. Subcutaneous garadacimab (Andembry), a once-monthly antibody that blocks activated Factor XII, followed in June 2025.
Each of those changed lives. None of them ended the dependence on chronic therapy. Patients still gave themselves shots every 2 weeks, took daily pills, or carried rescue medication everywhere. A single missed dose could mean an attack.
What Lonvo-Z Actually Does
Lonvo-z (lonvoguran ziclumeran, formerly known as NTLA-2002) is built around CRISPR/Cas9, the gene-editing tool that won the 2020 Nobel Prize in Chemistry. The drug is given as a single IV infusion. Inside the bloodstream, lipid nanoparticles carry the CRISPR machinery to the liver. There, the gene editor finds one specific gene called KLKB1 and inactivates it.
KLKB1 is the gene that tells the liver to make plasma kallikrein. Plasma kallikrein triggers bradykinin production. Bradykinin is what causes the swelling. By turning off KLKB1 in liver cells, lonvo-z aims to lower kallikrein and bradykinin permanently, at the source.
One infusion. One target gene. The edit is intended to be lifelong. That's the theory. HAELO was built to test whether it actually works in patients.
What HAELO Showed
HAELO was a randomized, double-blind, placebo-controlled Phase 3 trial. It enrolled 80 adolescents and adults aged 16 and older with Type I or Type II HAE. 52 patients received a single 50 mg dose of lonvo-z. 28 received placebo. The primary efficacy evaluation period ran from week 5 to week 28 (6 months of monthly attack tracking). 71% of patients had been on long-term prophylaxis at study entry and were required to discontinue those therapies in the weeks before dosing (Intellia, 2026).
Mean monthly attack rate landed at 0.26 in the lonvo-z arm versus 2.10 on placebo (p<0.0001). The trial met all key secondary endpoints with statistical significance. As of the data cutoff on February 10, 2026, every patient who received lonvo-z, either at baseline or after crossover from placebo at week 28, remained off long-term prophylaxis.
Safety so far has been favorable. The most common treatment-emergent events during the primary observation period were infusion-related reactions, headache, and fatigue. All adverse events at the data cutoff were mild or moderate. No serious adverse events were reported in the lonvo-z arm.
“If approved as a one-time treatment, I would expect lonvo-z to be an appealing option for many patients.”
Aleena Banerji, M.D., Massachusetts General Hospital, HAELO principal investigator
Intellia completed its BLA submission, and on September 8, 2026, the FDA accepted the application and granted it Priority Review with a target action date of March 10, 2027. The FDA has said it does not currently plan to hold an advisory committee meeting to discuss the application. That date is when the agency is expected to decide whether lonvo-z can be sold in the United States.
Why This Matters Beyond HAE
Phase 3 success is rare in any disease. Phase 3 success for in vivo gene editing had never happened before April 27, 2026. The therapeutic concept of delivering CRISPR to a specific tissue, editing a target gene, and changing a disease at its root has been tested in earlier-phase studies for transthyretin amyloidosis (Intellia's nex-z), familial hypercholesterolemia, sickle cell disease, and several rare metabolic conditions. None had reached pivotal-trial efficacy. HAELO is the first.
Success in one program doesn't guarantee success in the next. Intellia's own ATTR amyloidosis trials, MAGNITUDE and MAGNITUDE-2, were placed on FDA clinical hold in late 2025 after a serious liver adverse event, and the FDA lifted those holds in January and March 2026 with added liver monitoring. The biology of getting CRISPR safely into the right tissue, at the right dose, with durable effect and no off-target damage, is genuinely hard. HAELO showed it can be done in HAE. It didn't show it will work everywhere.
For patients in adjacent rare diseases, ATTR amyloidosis among them, alpha-1 antitrypsin deficiency, hereditary tyrosinemia, primary hyperoxaluria, the HAELO result is a signal worth tracking. The pathway is now demonstrably real. The first regulatory crossing has been mapped.
If You Have HAE: What to Do Today
Lonvo-z is not approved yet. The earliest possible U.S. availability is the first half of 2027, contingent on FDA review of the rolling BLA. Until then, current prophylactic therapies remain the standard. If you're on Takhzyro, Orladeyo, Cinryze, Andembry, or another preventive regimen, do not change anything without your HAE specialist.
First, watch for the HAELO peer-reviewed publication. Detailed safety, durability, and subgroup data will land in a major journal in the months ahead. The press release covers the topline. The full paper covers the nuance.
Second, ask your HAE specialist whether participation in the Intellia open-label extension or future post-approval follow-up is appropriate. Real-world durability data over years matters for a one-time edit, and patients who participate help establish that picture.
Third, watch the FDA action timeline. Once the BLA is complete in the second half of 2026, the agency will set a PDUFA target date. That date is when the agency commits to a decision. Approval, if it comes, is when lonvo-z becomes prescribable.
Fourth, the US Hereditary Angioedema Association maintains the most current patient-facing resources for treatment access, insurance questions, and clinical trial enrollment. Their patient services team can connect you with HAE specialists in your region.
If lonvo-z is approved, the next question becomes access. Pricing, insurance coverage, and which centers will administer the infusion are all unknowns. Approved gene therapies have so far carried list prices in the $1 million to $3 million range as one-time treatments. Whether lonvo-z follows that pattern, and how payers cover it, will determine whether the science actually reaches patients.
HAE has been a 144-year journey from Quincke's 1882 description to the first one-time gene-editing therapy. The next year will tell us whether that 144th year actually arrives at patients' bedsides.